The application of ibrutinib, the first-generation small-molecule BTK inhibitor and other, even more specific BTK inhibitors has significantly changed the treatment landscape for various B-cell lymphomas, including MCL [9–11]. This evidence concerns the gene BTK and mantle cell lymphoma.